Rengyun Liu

<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

Mingzhao Xing, Rengyun Liu, Xiaoli Liu et al. · Journal of Clinical Oncology · 2014 · 715 citations · Full text

Medicine, Genetics, Oncology +15

<i>TERT</i>Promoter Mutations and Their Association with<i>BRAF</i>V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer

Xiaoli Liu, Shen Qu, Rengyun Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 316 citations · Full text

Medicine, Genetics, Oncology +15

JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells

Rengyun Liu, Yuanyuan Zeng, Zhe Lei et al. · International Journal of Oncology · 2014 · 311 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Mortality Risk Stratification by Combining <i>BRAF </i>V600E and <i>TERT</i> Promoter Mutations in Papillary Thyroid Cancer

Rengyun Liu, Justin A. Bishop, Guangwu Zhu et al. · JAMA Oncology · 2016 · 289 citations

Medicine, Genetics, Oncology +14

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

Xiaoguang Shi, Rengyun Liu, Fulvio Basolo et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 203 citations · Full text

Medicine, Oncology, Cancer Genetics +15